Related Experiment Videos
Clinical aspects of peritoneal sclerosis
G C Cancarini1, M Sandrini, V Vizzardi
1Chair and Division of Nephrology, University and Spedali Civili Brescia, Italy. Giovanni.C.Cancarini@numerica.it
Journal of Nephrology
|January 19, 2002
Summary
Peritoneal sclerosis (PS) and sclerosing encapsulating peritonitis (SEP) are serious conditions in peritoneal dialysis (PD) patients. This review covers their causes, symptoms, diagnosis, and treatment.
Area of Science:
- Nephrology
- Gastroenterology
- Pathology
Background:
- Peritoneal sclerosis (PS) is common in long-term peritoneal dialysis (PD) patients.
- Sclerosing encapsulating peritonitis (SEP) is a severe, though infrequent, complication.
- SEP can manifest years after PD cessation and is not exclusive to PD patients.
Purpose of the Study:
- To review the clinical aspects of PS and SEP.
- To discuss the pathogenesis, clinical signs, diagnosis, and therapy of PS and SEP.
Main Methods:
- Literature review of clinical aspects of PS and SEP.
- Discussion of etiopathogenetic factors including PD solutions, peritonitis, drugs, and surgery.
Main Results:
- PS is often asymptomatic in PD patients.
- SEP is a severe syndrome linked to various abdominal conditions, drugs, and surgery.
- The primary cause of PS is poor biocompatibility of PD solutions.
Conclusions:
- SEP is a complex syndrome with multifactorial causes.
- Further research is needed to clarify the exact etiopathogenesis and nomenclature of SEP (EPS).
- Comprehensive understanding of PS and SEP is crucial for patient management in PD and post-PD care.